NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
Parabilis Medicines, Inc.

Parabilis Medicines, Inc.

PBLSNASDAQ
filed

Sector

Healthcare

Filed

May 19, 2026

About

Parabilis Medicines, Inc.

Parabilis Medicines is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease.

We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.

Our lead product candidate, zolucatetide, is, to our knowledge, the first and only investigational therapy that inhibits the b-catenin:TCF interaction, the critical downstream node of the Wnt/b-catenin pathway.

Parabilis Medicines, Inc. Overview

Ticker, listing venue and issuer profile

TickerPBLS
ExchangeNASDAQ
Statusfiled
SectorHealthcare
IndustryBiotechnology
CurrencyUSD
CIK Code1657677
CUSIP--
ISIN--

Offer & Key Dates

Pricing terms and IPO milestones

Price Range--
Offer Price--
Listing Price--
Current Price--
Shares Offered--
Shares Outstanding--
Offer Size--
Market Cap--
Filing DateMay 19, 2026
Priced Date--
Listed Date--

Financial Highlights

Historical financial performance

SEC Filings

Official documents from SEC EDGAR

Company Info

Contact and headquarters details

HeadquartersUnited States
Founded2015
Employees145
Phone(617) 945-9510
Address30 Acorn Park DriveCambridge, MA MAUnited States

Leadership

Key executives and officers

MM

Mathai Mammen, M.D., Ph.D.

Chairman, Chief Executive Officer and President

FB

Fawzi Benzaghou, M.D.

Chief Medical Officer

HH

Helen Ho, Ph.D.

Chief Business and Strategy Officer

TK

Thomas Kotarakos

Chief Financial Officer

RM

Rohin Mhatre, Ph.D.

Chief Technical Operations Officer

TJ

Teresa Jurgensen, J.D.

General Counsel

AB

Alexis Borisy

Director

EF

Edward Fitzgerald

Director

RK

Rick Klausner, M.D.

Director

AM

Alan M. Sebulsky

Director

Parabilis Medicines, Inc. IPO - FAQs

IPO (initial public offering) is the process through which a private company offers its shares to the public for the first time to raise equity capital from a broader base of public investors.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.